Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (21)

Dave Lunn

Ferdie Rombout

C. Laveille, C. Christin-Maitre*, C. Varin, Y. Tsouderos, and R. Jochemsen.

Hormone exposure and effects on Follicle-Stimulating Hormone (FSH) after nasal administration of Estradiol (E2) in postmenopausal women

Paolo Vicini

Integrated system models to understand disease status, progression and therapy: case studies

Joe Schafer

Multiple Imputation for Missing-Data Problems

Ivan Nestorov

Sensitivity Analysis of PBPK and PK/PD Models

Kimko, Hui C.

Iron kinetics: when drug loss by sampling is critical in data analysis

Karlsson Mats, Jonsson Niclas and Zingmark Per-Henrik

Models for sedation scores in acute stroke patients

J.G.Wright

Forward selection and other recipes for disaster

Philippe Jacqmin1, Ronald Gieschke2,4, Paul Jordan2,4, Jean-Louis Steimer2,4, Timothy Goggin2,3, Goonaseelan (Colin) Pillai2,3, Eric Snoeck1, Pascal Girard1.

Modeling drug induced changes in biomarkers without using drug concentrations: Introducing the K-PD model

NHG Holford1, S Bååthe 2, Mats Karlsson2

Auckland Bones and Summer Sun

Julie A Simpson 1,2,3; Leon Aarons 4; William E Collins 5; Geoffrey M Jeffrey 5; Nicholas J White 1,2;

The natural progression of P.falciparum malaria:- Investigation of a historical cohort of syphilis patients treated with malariatherapy.

Lewis B Sheiner

Dealing With Missing Data in Longitudinal Studies Through Modeling

E. N. Jonsson, F. Macintyre, I. James, W. Wild and S. Marshall

A mechanism based population PK/PD model of UK-279,276 in healthy volunteers and patients

Zingmark, Per-Henrik* Edenius, Charlotte* and Karlsson Mats O**

Dose-Concentration-FACS models for the monoclonal antibody ATM-027, developed for the treatment of Multiple Sclerosis (MS)

Vincent Duval and Mats O. Karlsson

Influence of LOQ on the pharmacokinetics parameters after an IV bolus dose

Fredrik Jonsson

Physiologically based pharmacokinetic modeling in risk assessment -Development of Bayesian population methods

Philip Lowe Ph.D

On mechanism based PK/PD modelling for direct drug-ligand binding systems

L. Aarons, M. Karlsson, F. Mentré, A.V. Peer, F. Rombout, H. Schaefer, J.-L. Steimer, I. Trocóniz

The role of modelling and simulation in the clinical development of anti-cancer agents

Gordon Graham and Leon Aarons

Bayesian Optimal Design Applied to Mixed Effect Pharmacokinetic Models

Timothy Goggin1,2Philippe Jacqmin4, Ronald Gieschke1,3, Goonaseelan (Colin) Pillai1,2, Eric Snoeck4, Pascal Girard4, Jean-Louis Steimer1,3.

Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug.